{"id":"jevtana","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Acute infectious disease","Acute nephropathy","Anemia","Asthenia","Breastfeeding (mother)","Dehydration","Disease of liver","Hyperbilirubinemia","Kidney disease","Leukopenia","Liver function tests abnormal","Nausea and vomiting","Neutropenic disorder","Nutritional disorder","Pregnancy, function","Radiation Therapy Involving Bone","Severe diarrhea","Thrombocytopenic disorder"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT01500720","NCT03258320","NCT01379339","NCT01751308","NCT02441517","NCT02254785","NCT06401980","NCT01755390","NCT01978873","NCT02441894","NCT01447225","NCT02044354","NCT01747239","NCT03257891","NCT01693549","NCT01718353","NCT06632977","NCT05005728","NCT05701007","NCT07213674","NCT01518283","NCT01956149","NCT01578655","NCT01852578","NCT02166658","NCT01650285","NCT02985957","NCT06168487","NCT06585007","NCT01558219","NCT03381326","NCT06085729","NCT03114254","NCT03392428","NCT01941550","NCT01308580","NCT01750866","NCT01830231","NCT01527929","NCT01668459","NCT01335204","NCT04337580","NCT01541007","NCT01616875","NCT01438307","NCT03263650","NCT01757171","NCT05563558","NCT02621190","NCT01528163"],"aliases":["Cabazitaxel"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"aiSummary":"","brandName":"Jevtana","companyId":"bayer","ecosystem":[],"mechanism":{"target":"Tubulin beta","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":{"revenueYear":2024,"annualRevenue":300,"revenueSource":"Verified: Sanofi AR","revenueCurrency":"USD","revenueConfidence":"verified"},"references":[],"biosimilars":[],"companyName":"Bayer","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"Jevtana","indications":{"approved":[{"name":"Metastatic Prostate Carcinoma","diseaseId":"metastatic-prostate-carcinoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01500720","phase":"Phase 2","title":"Randomized Phase II Study of Cabazitaxel Versus Topotecan in Small Cell Lung Cancer Patients With Progressive Disease During or After a First Line Platinum Based Chemotherapy","status":"COMPLETED","sponsor":"Sanofi","isPivotal":false,"enrollment":179,"indication":"Small Cell Lung Cancer","completionDate":"2014-04"},{"nctId":"NCT03258320","phase":"Phase 2","title":"A Phase II-III Study of Neoadjuvant Chemotherapy Involving Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Followed by Surgery for Patients With High Risk Prostate Cancer","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","isPivotal":true,"enrollment":300,"indication":"Prostate Cancer Patients","completionDate":"2027-12"},{"nctId":"NCT01379339","phase":"Phase 1","title":"Phase I Study of Cabazitaxel - Platinum Fluorouracil Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"Krzysztof Misiukiewicz","isPivotal":false,"enrollment":40,"indication":"Squamous Cell Carcinoma of the Head and Neck","completionDate":"2015-01"},{"nctId":"NCT01751308","phase":"Phase 1","title":"A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System","status":"COMPLETED","sponsor":"Sanofi","isPivotal":false,"enrollment":39,"indication":"Malignant Solid Tumor - Malignant Nervous System Neoplasm","completionDate":"2016-02"},{"nctId":"NCT02441517","phase":"Phase 4","title":"A Multicenter, Open-label, Single-arm, Study of Enzalutamide Re-Treatment in Metastatic Castration-Resistant Prostate Cancer, As First Treatment Post-Chemotherapy in Patients Who Have Previously Recei","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","isPivotal":false,"enrollment":4,"indication":"Metastatic Castration Resistant Prostate Cancer","completionDate":"2017-03-15"},{"nctId":"NCT02254785","phase":"Phase 2","title":"A Phase II, Randomized, Multi-center Study of Cabazitaxel Versus Abiraterone or Enzalutamide in Poor Prognosis-metastatic Castration-resistant Prostate Cancer","status":"UNKNOWN","sponsor":"British Columbia Cancer Agency","isPivotal":false,"enrollment":120,"indication":"Metastatic Castration-Resistant Prostatic Cancer","completionDate":"2020-05"},{"nctId":"NCT06401980","phase":"Phase 2","title":"Addition of Darolutamide to First Line Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): a Randomized Open Label Phase II Trial","status":"RECRUITING","sponsor":"Swiss Cancer Institute","isPivotal":false,"enrollment":162,"indication":"Metastatic Castration-resistant Prostate Cancer","completionDate":"2030-09"},{"nctId":"NCT01755390","phase":"Phase 1","title":"A Phase I Dose Finding Study of XRP6258 Administered as a Weekly 1-hour Intravenous Infusion to Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Sanofi","isPivotal":false,"enrollment":42,"indication":"Advanced Solid Tumor","completionDate":"2002-10"},{"nctId":"NCT01978873","phase":"Phase 3","title":"Randomized Phase III Trial Comparing Cabazitaxel Combination Hormone Therapy to Hormone Therapy Alone in Metastatic Prostate Cancer or High Risk Disease","status":"UNKNOWN","sponsor":"Örebro University, Sweden","isPivotal":true,"enrollment":400,"indication":"Prostate Cancer","completionDate":"2019-11"},{"nctId":"NCT02441894","phase":"Phase 4","title":"Cabazitaxel in Combination With Prednisolone With Primary Prophylaxis With PEG-G-CSF for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Sanofi","isPivotal":false,"enrollment":21,"indication":"Prostate Cancer","completionDate":"2016-11"},{"nctId":"NCT01447225","phase":"Phase 1","title":"A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Merrimack Pharmaceuticals","isPivotal":false,"enrollment":43,"indication":"Solid Tumors","completionDate":"2014-01"},{"nctId":"NCT02044354","phase":"Phase 3","title":"A Study of Patient Preference Between Cabazitaxel and Docetaxel in First-line Chemotherapy for Metastatic Castrate-resistant Prostate Cancer","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","isPivotal":true,"enrollment":195,"indication":"Metastatic Castration-resistant Prostate Cancer","completionDate":"2017-12-22"},{"nctId":"NCT01747239","phase":"Phase 2","title":"Cabazitaxel in Platinum Refractory Ovarian Cancer. A Phase II Trial","status":"TERMINATED","sponsor":"Vejle Hospital","isPivotal":false,"enrollment":4,"indication":"Ovarian Cancer","completionDate":"2014-07"},{"nctId":"NCT03257891","phase":"Phase 2","title":"Multicenter, Prospective, Non-randomized, Phase II Trial Designed to Evaluate the Activity of Cabazitaxel in Patients With Advanced Adreno-Cortical- Carcinoma Progressing After Previous Chemotherapy L","status":"UNKNOWN","sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","isPivotal":false,"enrollment":25,"indication":"Adrenocortical Carcinoma","completionDate":"2022-01-24"},{"nctId":"NCT01693549","phase":"Phase 2","title":"Phase II Study of Cabazitaxel as 2nd Line Treatment in Patients With HER-2 Negative Metastatic Breast Cancer Previously Treated With Taxanes","status":"COMPLETED","sponsor":"Hellenic Cooperative Oncology Group","isPivotal":false,"enrollment":84,"indication":"Breast Cancer","completionDate":"2017-07-20"},{"nctId":"NCT01718353","phase":"Phase 2","title":"Phase II Trial to Evaluate Benefit of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers and Mechanisms of Taxane Resist","status":"COMPLETED","sponsor":"Sanofi","isPivotal":false,"enrollment":63,"indication":"Prostate Cancer Metastatic","completionDate":"2015-08"},{"nctId":"NCT06632977","phase":"Phase 2","title":"PREcision DIagnostics in Prostate Cancer Treatment (PREDICT)","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","isPivotal":false,"enrollment":474,"indication":"Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","completionDate":"2034-10-11"},{"nctId":"NCT05005728","phase":"Phase 2","title":"Phase 2 Multiple-Dose, Multiple-Arm, Parallel Assignment Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of XmAb®20717 Alone or in Combination With Chemotherapy or Targeted Therap","status":"COMPLETED","sponsor":"Xencor, Inc.","isPivotal":false,"enrollment":72,"indication":"Metastatic Castration-Resistant Prostate Cancer","completionDate":"2025-06-10"},{"nctId":"NCT05701007","phase":"N/A","title":"Real World Evidence Study on Metastatic Prostate Cancer Patient Characteristics, Treatment Patterns and Outcomes in the Pirkanmaa Hospital District in Finland","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":1083,"indication":"Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration Resistant Prostate Cancer (mCRPC)","completionDate":"2024-04-10"},{"nctId":"NCT07213674","phase":"Phase 3","title":"A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cance","status":"RECRUITING","sponsor":"Amgen","isPivotal":true,"enrollment":750,"indication":"Metastatic Castration-resistant Prostate Cancer","completionDate":"2032-08-30"},{"nctId":"NCT01518283","phase":"Phase 2","title":"Phase II Study of Weekly Cabazitaxel for Advanced Prostate Cancer in \"Unfit\" Hormone-Refractory Patients Previously Treated With Docetaxel","status":"COMPLETED","sponsor":"Spanish Oncology Genito-Urinary Group","isPivotal":false,"enrollment":74,"indication":"Hormone Refractory Prostate Cancer","completionDate":"2016-07"},{"nctId":"NCT01956149","phase":"Phase 2","title":"Multicentre, Phase II Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Adenocarcinoma of the Oesophagogastric Junction and Stomach","status":"COMPLETED","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","isPivotal":false,"enrollment":65,"indication":"Gastric Cancer","completionDate":"2018-04-04"},{"nctId":"NCT01578655","phase":"Phase 3","title":"A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Pro","status":"COMPLETED","sponsor":"Achieve Life Sciences","isPivotal":true,"enrollment":630,"indication":"Prostate Cancer","completionDate":"2016-07"},{"nctId":"NCT01852578","phase":"Phase 2","title":"A Pilot Phase II Trial of Cabazitaxel in Patients With Metastatic NSCLC Progressing After Docetaxel-based Treatment","status":"COMPLETED","sponsor":"Hellenic Oncology Research Group","isPivotal":false,"enrollment":46,"indication":"NSCLC","completionDate":"2013-08"},{"nctId":"NCT02166658","phase":"Phase 2","title":"A Phase II Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)","status":"TERMINATED","sponsor":"AIO-Studien-gGmbH","isPivotal":false,"enrollment":8,"indication":"Breast Cancer, Lung Cancer","completionDate":"2018-01-18"},{"nctId":"NCT01650285","phase":"Phase 2","title":"Cabazitaxel and Radiation For Patients With Pathologically Determined Stage 3 Prostate Cancer and/or Patients With PSA Elevation (>0.1- < 2.0 ng/mL) Following Radical Prostatectomy","status":"TERMINATED","sponsor":"Brown University","isPivotal":false,"enrollment":5,"indication":"Prostate Cancer","completionDate":"2014-07"},{"nctId":"NCT02985957","phase":"Phase 2","title":"A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","isPivotal":false,"enrollment":351,"indication":"Prostate Cancer","completionDate":"2025-01-07"},{"nctId":"NCT06168487","phase":"Phase 1","title":"Phase I Non-Randomized, Unblinded, Single-Center Trial of Oral Telmisartan Alone or Combined With Selected Standard of Care Therapies for Prostate Cancer","status":"RECRUITING","sponsor":"Tyler J Curiel","isPivotal":false,"enrollment":36,"indication":"Prostate Cancer","completionDate":"2027-04-01"},{"nctId":"NCT06585007","phase":"Phase 3","title":"Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer: a Randomized Phase 3 Trial","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","isPivotal":true,"enrollment":246,"indication":"Castration-resistant Prostate Cancer, Oligoprogressive","completionDate":"2029-01-20"},{"nctId":"NCT01558219","phase":"Phase 2","title":"Open, Single-arm, Multicenter, Phase II Trial Investigating the Safety of Biweekly Cabazitaxel in Metastatic Castration Resistant Prostate Cancer Patients Previously Treated With a Docetaxel-containin","status":"COMPLETED","sponsor":"Tampere University Hospital","isPivotal":false,"enrollment":60,"indication":"Metastatic Prostate Cancer","completionDate":"2014-12"},{"nctId":"NCT03381326","phase":"N/A","title":"Biomarkers Study: Circulating Tumor Cells (CTC), Free DNA, Stem Cells and Epithelial-mesenchymal-transition (EMT) Related Antigens as Biomarkers of Activity of Cabazitaxel in Castration-resistant Pros","status":"UNKNOWN","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","isPivotal":false,"enrollment":104,"indication":"Prostate Cancer, Metastatic Cancer","completionDate":"2023-12"},{"nctId":"NCT06085729","phase":"Phase 1","title":"Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":30,"indication":"Prostate Cancer","completionDate":"2027-12-31"},{"nctId":"NCT03114254","phase":"Phase 2","title":"A Phase II Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis","status":"COMPLETED","sponsor":"University Hospitals Bristol and Weston NHS Foundation Trust","isPivotal":false,"enrollment":17,"indication":"Penile Neoplasm","completionDate":"2016-11-16"},{"nctId":"NCT03392428","phase":"Phase 2","title":"TheraP: A Randomised Phase 2 Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (ANZUP Protocol 1603)","status":"COMPLETED","sponsor":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","isPivotal":false,"enrollment":201,"indication":"Cancer of the Prostate, Metastatic Cancer","completionDate":"2021-12-31"},{"nctId":"NCT01941550","phase":"Phase 2","title":"Neoadjuvant Chemotherapy With Cabazitaxel in High Risk Prostate Cancer Patients Prior to Radical Prostatectomy","status":"TERMINATED","sponsor":"RWTH Aachen University","isPivotal":false,"enrollment":11,"indication":"High-Risk Cancer","completionDate":"2016-01"},{"nctId":"NCT01308580","phase":"Phase 3","title":"Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate C","status":"COMPLETED","sponsor":"Sanofi","isPivotal":true,"enrollment":1200,"indication":"Prostate Cancer","completionDate":"2015-08"},{"nctId":"NCT01750866","phase":"Phase 2","title":"Efficacy and Toxicity of Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer With Progression After Treatment With Docetaxel","status":"WITHDRAWN","sponsor":"Case Comprehensive Cancer Center","isPivotal":false,"enrollment":0,"indication":"Castrate-resistant Metastatic Prostate Cancer","completionDate":"2013-10"},{"nctId":"NCT01830231","phase":"Phase 2","title":"A Randomised Phase II/III Study of Cabazitaxel Versus Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium","status":"UNKNOWN","sponsor":"Associació per a la Recerca Oncologica, Spain","isPivotal":true,"enrollment":372,"indication":"Urothelium Transitional Cell Carcinoma","completionDate":"2016-11"},{"nctId":"NCT01527929","phase":"Phase 1","title":"An Open-label Pharmacokinetic and Safety Study of Cabazitaxel in Patients With Solid Tumors With Moderately and Severely Impaired and With Normal Renal Function","status":"COMPLETED","sponsor":"Sanofi","isPivotal":false,"enrollment":25,"indication":"Neoplasm Malignant","completionDate":"2013-11"},{"nctId":"NCT01668459","phase":"Phase 2","title":"Cabazitaxel in Platinum Pre-treated Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma Who Developed Disease Progression Within 12 Months of Platinum Based Chemotherapy.","status":"COMPLETED","sponsor":"Dr Anjali Zarkar","isPivotal":true,"enrollment":20,"indication":"Transitional Cell Carcinoma","completionDate":"2017-11"},{"nctId":"NCT01335204","phase":"Phase 1","title":"Phase Ib/IIa Study of Cabazitaxel Plus Bavituximab for Patients With Castration-resistant Prostate Cancer Previously Treated With Chemotherapy","status":"TERMINATED","sponsor":"Medical University of South Carolina","isPivotal":false,"enrollment":4,"indication":"Prostate Cancer, Prostatic Neoplasms","completionDate":"2013-03"},{"nctId":"NCT04337580","phase":"Phase 2","title":"A Phase II Trial of FASN Inhibition by Omeprazole in Combination With Cabazitaxel in Patients With Docetaxel- and Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","isPivotal":false,"enrollment":50,"indication":"Prostate Cancer, Refractory Cancer","completionDate":"2028-03"},{"nctId":"NCT01541007","phase":"Phase 2","title":"A Randomized, Open Label, Multicenter, Phase II Trial Comparing The Conventional 3 Weekly Schedule Of Cabazitaxel With A Weekly Regimen In Patients With Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Jeffrey Yachnin M.D., PhD.","isPivotal":false,"enrollment":100,"indication":"Metastatic Castration Resistant Prostate Cancer","completionDate":"2015-10"},{"nctId":"NCT01616875","phase":"Phase 2","title":"A Phase II Trial of Combination Cabazitaxel and Cisplatin Chemotherapy in the Neo-adjuvant Treatment of Transitional Cell Carcinoma of the Urinary Bladder","status":"COMPLETED","sponsor":"University Hospitals Bristol and Weston NHS Foundation Trust","isPivotal":false,"enrollment":28,"indication":"Infiltrating Bladder Urothelial Carcinoma","completionDate":"2023-01-04"},{"nctId":"NCT01438307","phase":"Phase 2","title":"Phase II Study of a Novel Taxane (Cabazitaxel-XRP6258) in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","isPivotal":false,"enrollment":28,"indication":"Non-small Cell Lung Cancer (NSCLC), Stage IV NSCLC","completionDate":"2015-09"},{"nctId":"NCT03263650","phase":"Phase 2","title":"Randomized Phase II Study of Olaparib Maintenance Following Cabazitaxel-Carboplatin Induction Chemotherapy in Men With Aggressive Variant Prostate Cancer (AVPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":96,"indication":"Prostate Cancer Aggressiveness, Prostate Carcinoma","completionDate":"2026-06-30"},{"nctId":"NCT01757171","phase":"Phase 2","title":"An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","isPivotal":false,"enrollment":85,"indication":"Gastric Adenocarcinoma, Gastroesophageal Adenocarcinoma","completionDate":"2017-06"},{"nctId":"NCT05563558","phase":"Phase 2","title":"A Phase 2 Clinical Trial of Pembrolizumab in Combination With Carboplatin and Cabazitaxel in Aggressive Variant Metastatic Castration Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Fundacion Oncosur","isPivotal":false,"enrollment":42,"indication":"Prostate Cancer Metastatic","completionDate":"2026-11-01"},{"nctId":"NCT02621190","phase":"Phase 2","title":"Non-randomized Phase 2 Open-label Multicenter Study Determining the Response to Cabazitaxel in Metastatic Prostate Cancer (mCRPC) Patients With AR-V7 Positive Circulating Tumor Cells (CTCs): CARVE","status":"WITHDRAWN","sponsor":"Erasmus Medical Center","isPivotal":false,"enrollment":0,"indication":"Prostatic Neoplasms","completionDate":"2019-06"},{"nctId":"NCT01528163","phase":"Phase 2","title":"Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-based Therapy.","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","isPivotal":false,"enrollment":101,"indication":"Squamous Cell Carcinoma of the Head and Neck","completionDate":"2014-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"_revenueScrapedAt":"2026-04-08 13:59:05.860915+00","biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":16,"withResults":4},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}